Other grades of this product :
| Vonoprazan FuMarate Basic information |
| Product Name: | Vonoprazan FuMarate | | Synonyms: | 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate;Vonoprazan FuMarate###NA;1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate;Vonoprazan-025-Salt1;Voranomazin;Vonoprazan FuMarate USP/EP/BP;Vonoprazan fumarate,TAK-438,Takecab;Vonoprazan fumarate 13C D3 | | CAS: | 881681-01-2 | | MF: | C21H20FN3O6S | | MW: | 461.46 | | EINECS: | 1592732-453-0 | | Product Categories: | | Mol File: | 881681-01-2.mol |
| Vonoprazan FuMarate Chemical Properties |
| solubility | DMSO: 50 mg/mL (108.35 mM) |
| Vonoprazan FuMarate Usage And Synthesis |
| benefits | Compared with traditional irreversible proton pump inhibitors (such as omeprazole, esomeprazole, etc.), Vonoprazan fumarate advantages:① The onset of action is good, and the maximum acid-suppressing effect will be achieved on the first day of administration;② Oral administration, not affected by gastric acid damage;③It can improve the phenomenon of acid breakthrough at night. | | General Description | Vonoprazan fumarate (TAK-438) is a new oral anti-gastric acid drug jointly launched by Takeda Pharmaceutical and Otsuka Pharmaceutical. It can be used for the treatment of erosive esophagitis, gastric ulcer and duodenal ulcer. | | Mechanism of action | Vonoprazan fumarate is a potassium ion (K+) competitive acid blocker (P-CAB), which is a reversible proton pump inhibitor. It can inhibit the combination of K+ and H+-K+-ATPase (proton pump), so that secretion of gastric acid is terminated. Vonoprazan fumarate has a strong and lasting inhibitory effect on gastric acid secretion. |
| Vonoprazan FuMarate Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye